A better summary measure would be useful, but it is unclear whether there will ever be sufficiently little variation in valuation to design methods in a way that does not require repeated and costly reevaluation of assumptions.
Jeromie M. Ballreich, PhD, MS
Advertisement
Articles by Jeromie M. Ballreich, PhD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
4
Contributor: Why Public Health Keeps Failing—and How to Fix It
5
